Thromboembolic and bleeding complications following primary total knee arthroplasty
- 1 October 2021
- journal article
- research article
- Published by British Editorial Society of Bone & Joint Surgery in The Bone & Joint Journal
- Vol. 103-B (10) , 1571-1577
Abstract
Aims: The aim of this study is to compare the effectiveness and safety of thromboprophylactic treatments in patients undergoing primary total knee arthroplasty (TKA). Methods: Using nationwide medical registries, we identified patients with a primary TKA performed in Denmark between 1 January 2013 and 31 December 2018 who received thromboprophylactic treatment. We examined the 90-day risk of venous thromboembolism (VTE), major bleeding, and all-cause mortality following surgery. We used a Cox regression model to compute hazard ratios (HRs) with 95% confidence intervals (CIs) for each outcome, pairwise comparing treatment with dalteparin or dabigatran with rivaroxaban as the reference. The HRs were both computed using a multivariable and a propensity score matched analysis. Results: We identified 27,736 primary TKA patients who received thromboprophylactic treatment (rivaroxaban (n = 18,846); dalteparin (n = 5,767); dabigatran (n = 1,443); tinzaparin (n = 1,372); and enoxaparin (n = 308)). In the adjusted multivariable analysis and compared with rivaroxaban, treatment with dalteparin (HR 0.68 (95% CI 0.49 to 0.92)) or dabigatran (HR 0.31 (95% CI 0.13 to 0.70)) was associated with a decreased risk of VTE. No statistically significant differences were observed for major bleeding or all-cause mortality. The propensity score matched analysis yielded similar results. Conclusion: Treatment with dalteparin or dabigatran was associated with a decreased 90-day risk of VTE following primary TKA surgery compared with treatment with rivaroxaban. Cite this article: Bone Joint J 2021;103-B(10):1571–1577.Keywords
This publication has 30 references indexed in Scilit:
- Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisonsBMJ, 2012
- Existing data sources for clinical epidemiology: The Danish Knee Arthroplasty RegisterClinical Epidemiology, 2012
- Prevention of VTE in Orthopedic Surgery PatientsChest, 2012
- The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of PatientsBMC Medical Research Methodology, 2011
- A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplastyJournal of Thrombosis and Haemostasis, 2010
- Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: A pooled analysis of three trialsThrombosis Research, 2010
- Venous thromboembolism discharge diagnoses in the Danish National Patient Registry should be used with cautionJournal of Clinical Epidemiology, 2010
- Apixaban or Enoxaparin for Thromboprophylaxis after Knee ReplacementNew England Journal of Medicine, 2009
- A Modification of the Elixhauser Comorbidity Measures Into a Point System for Hospital Death Using Administrative DataMedical Care, 2009
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) StatementEpidemiology, 2007